Drugs / SY-4798
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05498519 | Apr 2021 → Apr 2024 | neoplasm | Shouyao Holdings (Beijing) Co. LTD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY-4798 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05498519 ↗ |
| Action | Inhibit | “inhibitor of FGFR4” NCT05498519 ↗ |
| Target | FGFR4 | “inhibitor of FGFR4” NCT05498519 ↗ |